11. suragani rn, cadena sm, cawley sm, et al. transforming growth factor- b superfamily ligand trap ace-536 corrects anemia by promoting late-stage erythropoiesis. nat med. 2014;20(4):408-414. 12. fenaux p, platzbecker u, mufti gj, et al. luspatercept in patients with lower-risk myelodysplastic syndromes. n engl j med. 2020;382(2): 140-151. 13. cheson bd, greenberg pl, bennett jm, et al. clinical application and proposal for modi fi cation of the international working group (iwg) response criteria in myelodysplasia. blood. 2006;108(2):419-425. 14. greenberg pl, tuechler h, schanz j, et al. revised international prognostic scoring system for myelodysplastic syndromes. 2012; 120(12):2454-2465

HIGHLIGHTS

• who: . Suragani RN and colleagues from the Aged healthy mice acquire clonal hematopoiesis mutations Desmond Wai Loon Chin, * Tetsuichi Yoshizato, * Stina Virding Culleton [1] Francesca Grasso, Magdalena Barbachowska, Seishi Ogawa, , Sten Eirik WJacobsen, , u2020 and Petter S. Woll1, u2020 , Department of Medicine Huddinge, Center for Hematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden have published the research: 11. Suragani RN, Cadena SM, Cawley SM, et al. Transforming growth factor- b superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med. 2014;20(4):408-414. 12. Fenaux P, Platzbecker U, Mufti GJ, et . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.